Patients under 21 with breast or colorectal cancer more likely to have aggressive disease
the ONA take:
According to two studies presented at the 2014 Clinical Congress of the American College of Surgeons in San Francisco, California, when breast and colorectal cancers occur in children, the diseases are aggressive.
Researchers at Seattle Children's Hospital in Seattle, Washington sought to investigate how breast cancer progresses when diagnosed in patients under age 21. Researchers identified 574 patients aged 21 or younger with breast cancer from the National Cancer Data Base of the American College of Surgeons and American Cancer Society. Results showed that younger patients were more likely to be African American, male, and uninsured.
Furthermore, these patients had worse outcomes that adult patients. Researchers also found a large delay between surgical treatment and radiation therapy. The delay is something the researchers hope to investigate further.
The other study was conducted by researchers at the Maine Medical Center in Portland, Maine who wanted to assess the outcomes of younger patients diagnosed with colorectal cancer. They identified 920 patients age 21 or younger. They found that younger patients were more likely diagnosed with advanced disease and found to have more aggressive tumors. Pediatric patients also had lower 5-year survival rates compared young adults.
When breast and colorectal cancers occur in children, the diseases are aggressive.
Breast and colorectal cancers rarely occur in children, but when they do, these conditions are more precarious, according to a pair of National Cancer Data Base (NCDB) studies presented this week at the 2014 Clinical Congress of the American College of Surgeons. Both breast cancer and colon cancer are known as adult conditions.
According to the American Cancer Society, 95 percent of new breast cancer cases occur in women age 40 and older. Colorectal cancer is also largely an adult cancer, with 90 percent of cases occurring in people who are age 50 and older.
- Study Identifies Factors Associated With Hearing Loss in Polycythemia Vera
- Ezh2 Inhibitors May Offer Cure for Chronic Myelogenous Leukemia
- Ruxolitinib: A Targeted Treatment Option for Patients with Polycythemia Vera
- Incontinence Affects QOL for Survivors of Gynecologic Cancers
- Robotic Surgery Provides Good Outcomes and Survival in Oropharyngeal Cancer
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Tumor Markers (Fact Sheet)
- Implementing a Distress Screening Process for Cancer Patients
- Ruxolitinib Effective as Long-term Treatment Option for Polycythemia Vera
- Definitive IMRT Associated With Shorter Feeding Tube Placement Duration in HNC
- SBRT Improves Overall and Disease-Specific Survival in Stage I NSCLC
- Patients Receiving RT in APBI Facilities Despite Eligibility for Observation
- Prolonged Imatinib Therapy Improves Likelihood of Deeper Molecular Response
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|